Targeting FGF for third-line treatment of mRCC

被引：0
|
作者：
Sarah Payton
机构：
来源：
Nature Reviews Urology | 2014年 / 11卷 / 4期
关键词：
D O I：
10.1038/nrurol.2014.55
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：186 / 186
相关论文
共 50 条
  • [31] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Akitaka Makiyama
    Kohei Arimizu
    Gen Hirano
    Chinatsu Makiyama
    Yuzo Matsushita
    Tsuyoshi Shirakawa
    Hirofumi Ohmura
    Masato Komoda
    Keita Uchino
    Kyoko Inadomi
    Shuji Arita
    Hiroshi Ariyama
    Hitoshi Kusaba
    Yudai Shinohara
    Miyuki Kuwayama
    Tatsuhiro Kajitani
    Hisanobu Oda
    Taito Esaki
    Koichi Akashi
    Eishi Baba
    [J]. Gastric Cancer, 2018, 21 : 464 - 472
  • [32] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Makiyama, Akitaka
    Arimizu, Kohei
    Hirano, Gen
    Makiyama, Chinatsu
    Matsushita, Yuzo
    Shirakawa, Tsuyoshi
    Ohmura, Hirofumi
    Komoda, Masato
    Uchino, Keita
    Inadomi, Kyoko
    Arita, Shuji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Shinohara, Yudai
    Kuwayama, Miyuki
    Kajitani, Tatsuhiro
    Oda, Hisanobu
    Esaki, Taito
    Akashi, Koichi
    Baba, Eishi
    [J]. GASTRIC CANCER, 2018, 21 (03) : 464 - 472
  • [33] Second- and third-line treatment for pediatric patients failing ART
    Giaquinto, C.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 21 : 68 - 68
  • [34] First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC)
    Heng, Daniel Yick Chin
    Rini, Brian I.
    Lee, Jae-Lyun
    Kroeger, Nils
    Srinivas, Sandy
    Harshman, Lauren Christine
    Knox, Jennifer J.
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishampayan, Ulka N.
    Agarwal, Neeraj
    Pal, Sumanta Kumar
    Tan, Min-Han
    Rha, Sun Young
    Yuasa, Takeshi
    Donskov, Frede
    Bamias, Aristotelis
    North, Scott A.
    Choueiri, Toni K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] After standard treatment, do the second-line and third-line treatments make sense?
    Sabbatini, R
    Maur, M
    Mucciarini, C
    Conte, PF
    [J]. TUMORI, 2003, : S33 - S34
  • [36] Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer
    Zardavas, Dimitrios
    Meisel, Alexander
    Samaras, Panagiotis
    Knuth, Alexander
    Renner, Christoph
    Pestalozzi, Bernhard C.
    Stenner-Liewen, Frank
    [J]. CASE REPORTS IN ONCOLOGY, 2011, 4 (01): : 16 - 18
  • [37] Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization
    Germano Scevola
    Giorgio Loreni
    Marco Rastelli
    Stefano Sposato
    Sara Ramponi
    Vittorio Miele
    [J]. Medical Oncology, 2017, 34
  • [38] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Takeshi Kawakami
    Nozomu Machida
    Hirofumi Yasui
    Masahiro Kawahira
    Sadayuki Kawai
    Yosuke Kito
    Yukio Yoshida
    Satoshi Hamauchi
    Takahiro Tsushima
    Akiko Todaka
    Tomoya Yokota
    Kentaro Yamazaki
    Akira Fukutomi
    Yusuke Onozawa
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 78 : 809 - 814
  • [39] Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib
    Mayer, K.
    Gielen, G. H.
    Willinek, W.
    Muller, M. C.
    Wolf, D.
    [J]. LEUKEMIA, 2014, 28 (04) : 976 - 977
  • [40] Efficacy of apatinib as third-line treatment of advanced colorectal cancer and prognostic analysis
    Wang, Juchao
    Sun, Qiang
    Zhao, Jian
    Li, Zengming
    Kou, Dan
    Qu, Dongxiang
    [J]. JOURNAL OF BUON, 2021, 26 (01): : 93 - 100
12345